We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toOpening-Keynote-Patient-Advocacy-in-Rare-Disease-Duchene-Muscular-Dystrophy

Pharmacovigilance and Risk Management Strategies Conference

Opening Keynote: Patient Advocacy in Rare Disease: Duchenne Muscular Dystrophy

    Session Chair(s)
      William  Gregory, PhD

      William Gregory, PhD

      • Safety and Risk Management
      • Pfizer Inc, United States
    Rare diseases present special challenges for patients, caregivers, and those who seek to develop and provide safe and effective treatments. One disease that presents such challenges is Duchenne Muscular Dystrophy (DMD), a genetic disorder that is characterized by progressive muscle degeneration and weakness caused by an abnormality in the dystrophin complex in muscle fiber. Development of safe and effective biopharmaceutical interventions has been enigmatic. This session will provide an overview of this devastating disease, patient advocacy efforts, and the partnership network that has emerged to facilitate development of evidence-based interventions.
      Christine  McSherry, BSN, RN


      Christine McSherry, BSN, RN

      • Executive Director
      • Jett Foundation, United States